JP2016105731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016105731A5 JP2016105731A5 JP2016048499A JP2016048499A JP2016105731A5 JP 2016105731 A5 JP2016105731 A5 JP 2016105731A5 JP 2016048499 A JP2016048499 A JP 2016048499A JP 2016048499 A JP2016048499 A JP 2016048499A JP 2016105731 A5 JP2016105731 A5 JP 2016105731A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- copy number
- amplification
- subject
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039189 Transcription factor Maf Human genes 0.000 claims 58
- 210000000988 bone and bone Anatomy 0.000 claims 22
- 230000003321 amplification Effects 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims 21
- 206010027476 Metastases Diseases 0.000 claims 19
- 230000014509 gene expression Effects 0.000 claims 19
- 230000009401 metastasis Effects 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 239000000523 sample Substances 0.000 claims 16
- 206010060862 Prostate cancer Diseases 0.000 claims 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 15
- 238000011282 treatment Methods 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 14
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 230000015556 catabolic process Effects 0.000 claims 9
- 238000006731 degradation reaction Methods 0.000 claims 9
- 102000014128 RANK Ligand Human genes 0.000 claims 6
- 108010025832 RANK Ligand Proteins 0.000 claims 6
- 239000013068 control sample Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 230000005945 translocation Effects 0.000 claims 6
- 206010027452 Metastases to bone Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 229940111134 coxibs Drugs 0.000 claims 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 4
- 229940043355 kinase inhibitor Drugs 0.000 claims 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims 4
- 229960005562 radium-223 Drugs 0.000 claims 4
- 229940122361 Bisphosphonate Drugs 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 108020004635 Complementary DNA Proteins 0.000 claims 3
- 208000003076 Osteolysis Diseases 0.000 claims 3
- 150000004663 bisphosphonates Chemical class 0.000 claims 3
- 238000010804 cDNA synthesis Methods 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 238000001794 hormone therapy Methods 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 229940097000 DKK-1 inhibitor Drugs 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 229960004015 calcitonin Drugs 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 229940079488 strontium ranelate Drugs 0.000 claims 2
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000004171 Cathepsin K Human genes 0.000 claims 1
- 108090000625 Cathepsin K Proteins 0.000 claims 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims 1
- 230000004544 DNA amplification Effects 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000008108 Osteoprotegerin Human genes 0.000 claims 1
- 108010035042 Osteoprotegerin Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000003491 array Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 101150095688 maf gene Proteins 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000003498 protein array Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713318P | 2012-10-12 | 2012-10-12 | |
| US61/713,318 | 2012-10-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536237A Division JP6074049B2 (ja) | 2012-10-12 | 2013-10-09 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017340A Division JP6636067B2 (ja) | 2012-10-12 | 2018-02-02 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016105731A JP2016105731A (ja) | 2016-06-16 |
| JP2016105731A5 true JP2016105731A5 (enExample) | 2017-06-15 |
| JP6446381B2 JP6446381B2 (ja) | 2018-12-26 |
Family
ID=49998595
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536237A Active JP6074049B2 (ja) | 2012-10-12 | 2013-10-09 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| JP2016048499A Active JP6446381B2 (ja) | 2012-10-12 | 2016-03-11 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| JP2018017340A Active JP6636067B2 (ja) | 2012-10-12 | 2018-02-02 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536237A Active JP6074049B2 (ja) | 2012-10-12 | 2013-10-09 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017340A Active JP6636067B2 (ja) | 2012-10-12 | 2018-02-02 | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140105918A1 (enExample) |
| EP (2) | EP2906718B1 (enExample) |
| JP (3) | JP6074049B2 (enExample) |
| KR (1) | KR101872965B1 (enExample) |
| CN (1) | CN104995313A (enExample) |
| AU (1) | AU2016213773B2 (enExample) |
| BR (1) | BR112015008255B1 (enExample) |
| CA (1) | CA2888122A1 (enExample) |
| DK (1) | DK2906718T3 (enExample) |
| ES (2) | ES2906586T3 (enExample) |
| HK (1) | HK1213946A1 (enExample) |
| MX (1) | MX365421B (enExample) |
| WO (1) | WO2014057357A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012045905A2 (es) | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| KR102226219B1 (ko) | 2012-06-06 | 2021-03-10 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 폐암 전이의 진단, 예후 및 치료 방법 |
| JP6074049B2 (ja) | 2012-10-12 | 2017-02-01 | インバイオモーション エセ．エレ． | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| US20140314792A1 (en) | 2013-03-15 | 2014-10-23 | Institució Catalana De Recerca I Estudis Avançats | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| US11206976B2 (en) * | 2014-10-16 | 2021-12-28 | New York University | Method and system for simultaneous decomposition of multiple hyperspectral datasets and signal recovery of unknown fluorophores in a biochemical system |
| BR112017012515A2 (en) | 2014-12-11 | 2018-01-02 | Inbiomotion S.L. | binding members for human c-maf |
| US20180303830A1 (en) * | 2015-06-22 | 2018-10-25 | Thomas Jefferson University | Cancers expressing ccr5 and methods of treatment of same |
| PL3458610T3 (pl) * | 2016-05-25 | 2021-11-22 | Inbiomotion S.L. | Leczenie raka piersi w oparciu o status c-MAF |
| CZ2016821A3 (cs) * | 2016-12-22 | 2018-07-04 | České vysoké učení technické v Praze | Kombinace pro radionuklidovou terapii pro použití jako léčivo |
| BR112020010192A2 (pt) | 2017-11-22 | 2020-10-13 | Inbiomotion S.L. | tratamento terapêutico de câncer de mama com base no status de c-maf |
| TW202012637A (zh) * | 2018-04-24 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2024130224A2 (en) * | 2022-12-16 | 2024-06-20 | Purdue Research Foundation | Stapled peptides for sensitization of cancer to treatment |
| CN116287250B (zh) * | 2023-01-18 | 2025-12-16 | 中山大学附属第七医院(深圳) | 一种前列腺癌骨转移诊断、治疗和/或预后的标志物及其应用 |
| CN119007946B (zh) * | 2024-08-02 | 2025-02-07 | 连云港市第二人民医院(连云港市临床肿瘤研究所) | 一种用于肿瘤患者的全病程智能化医疗管理系统 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| JP2000508895A (ja) | 1996-04-05 | 2000-07-18 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物系における外来遺伝子の発現を調節するためのホルモン媒介方法と、それに関連した産物 |
| CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| EE04911B1 (et) | 1999-03-15 | 2007-10-15 | Axys Pharmaceuticals, Inc. | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| US6525036B2 (en) | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
| ATE348617T1 (de) | 2000-02-16 | 2007-01-15 | Astellas Pharma Inc | Heilmittel gegen durch endothelin verursachte erkrankungen |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| DK2087908T3 (en) | 2001-06-26 | 2018-07-23 | Amgen Inc | ANTIBODIES AGAINST OPGL |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| JP4579581B2 (ja) * | 2003-12-08 | 2010-11-10 | 株式会社グリーンペプタイド | 副甲状腺ホルモン関連タンパク質のｈｌａ−ａ２４またはｈｌａ−ａ２結合ペプチド |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1706137A2 (en) | 2004-01-21 | 2006-10-04 | Chiron Corporation | M-csf muteins and uses thereof |
| CA2567942A1 (en) | 2004-05-26 | 2005-12-08 | Green Peptide Co., Ltd. | Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP3211086B1 (en) | 2005-09-20 | 2021-06-09 | Menarini Silicon Biosystems S.p.A. | Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| JP5142288B2 (ja) * | 2006-04-05 | 2013-02-13 | 公立大学法人横浜市立大学 | 前立腺癌の予後判定方法及びそのための診断薬 |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| US8623361B2 (en) | 2007-05-24 | 2014-01-07 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| US20110123617A1 (en) | 2007-10-18 | 2011-05-26 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| EP2296654A4 (en) | 2008-06-06 | 2012-04-18 | Univ Health Network | 8-HYDROXYCHINOLINE DERIVATIVES FOR THE TREATMENT OF CRUISING HEMATOLOGICAL DISEASES |
| EP2400851A4 (en) * | 2009-02-25 | 2012-09-05 | Merrion Res Iii Ltd | COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES |
| WO2012045905A2 (es) | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
| ES2379918B1 (es) * | 2010-10-06 | 2013-05-10 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama. |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| KR102226219B1 (ko) | 2012-06-06 | 2021-03-10 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 폐암 전이의 진단, 예후 및 치료 방법 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| JP6074049B2 (ja) * | 2012-10-12 | 2017-02-01 | インバイオモーション エセ．エレ． | ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20140314792A1 (en) | 2013-03-15 | 2014-10-23 | Institució Catalana De Recerca I Estudis Avançats | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| MX362041B (es) | 2013-10-09 | 2019-01-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| HUE058328T2 (hu) | 2014-06-17 | 2022-07-28 | Asherman Therapy S L | Õssejtterápia endometriális patológiás állapotokban |
| BR112017012515A2 (en) | 2014-12-11 | 2018-01-02 | Inbiomotion S.L. | binding members for human c-maf |
| PL3458610T3 (pl) | 2016-05-25 | 2021-11-22 | Inbiomotion S.L. | Leczenie raka piersi w oparciu o status c-MAF |
| BR112020010192A2 (pt) | 2017-11-22 | 2020-10-13 | Inbiomotion S.L. | tratamento terapêutico de câncer de mama com base no status de c-maf |
-
2013
- 2013-10-09 JP JP2015536237A patent/JP6074049B2/ja active Active
- 2013-10-09 CA CA2888122A patent/CA2888122A1/en not_active Abandoned
- 2013-10-09 HK HK16101721.6A patent/HK1213946A1/zh unknown
- 2013-10-09 US US14/050,262 patent/US20140105918A1/en not_active Abandoned
- 2013-10-09 EP EP13821939.9A patent/EP2906718B1/en active Active
- 2013-10-09 US US14/435,128 patent/US10114022B2/en active Active
- 2013-10-09 WO PCT/IB2013/002866 patent/WO2014057357A2/en not_active Ceased
- 2013-10-09 EP EP19174485.3A patent/EP3553186B1/en active Active
- 2013-10-09 ES ES19174485T patent/ES2906586T3/es active Active
- 2013-10-09 KR KR1020157012297A patent/KR101872965B1/ko active Active
- 2013-10-09 DK DK13821939.9T patent/DK2906718T3/da active
- 2013-10-09 BR BR112015008255-6A patent/BR112015008255B1/pt active IP Right Grant
- 2013-10-09 ES ES13821939T patent/ES2744244T3/es active Active
- 2013-10-09 CN CN201380060218.XA patent/CN104995313A/zh active Pending
- 2013-10-09 MX MX2015004610A patent/MX365421B/es active IP Right Grant
-
2016
- 2016-03-11 JP JP2016048499A patent/JP6446381B2/ja active Active
- 2016-08-10 AU AU2016213773A patent/AU2016213773B2/en active Active
-
2018
- 2018-02-02 JP JP2018017340A patent/JP6636067B2/ja active Active
- 2018-09-18 US US16/134,449 patent/US11041861B2/en active Active
-
2021
- 2021-06-04 US US17/339,024 patent/US11892453B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016105731A5 (enExample) | ||
| JP2018078911A5 (enExample) | ||
| JP2016516403A5 (enExample) | ||
| JP2016539625A5 (enExample) | ||
| JP6781184B2 (ja) | がん転移の予後診断および処置のための方法 | |
| JP6105012B2 (ja) | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ | |
| JP2015521050A5 (enExample) | ||
| WO2013182912A4 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| JP2013541339A5 (enExample) | ||
| CA2948351C (en) | Biomarkers for response to pi3k inhibitors | |
| JP2019523641A5 (enExample) | ||
| JP6550045B2 (ja) | 乳がんに由来する骨の転移がんの予後診断および処置のための方法 | |
| KR102867720B1 (ko) | c-MAF 상태에 기초한 유방암의 치료 | |
| Wang et al. | Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway | |
| JP6735277B2 (ja) | 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 | |
| CN105324491A (zh) | 用于癌症转移的诊断和治疗的方法 | |
| CN104995313A (zh) | 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法 | |
| JP2012522756A5 (enExample) | ||
| Zhang et al. | Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer | |
| JP2016520289A5 (enExample) | ||
| JP6612232B2 (ja) | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 | |
| US20160024206A1 (en) | Methods for the Treatment and the Prognostic Assessment of Malignant Pleural Mesothelioma | |
| JP2023520475A (ja) | 免疫抗がん療法に対するバイオマーカーおよびその用途 | |
| JP2022515416A (ja) | 免疫チェックポイント阻害療法からの利益を予測する方法 | |
| Sartore-Bianchi et al. | Plasticity of resistance and sensitivity to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |